BioSpace News Archive

BioMarin Pharmaceutical Inc. will present updated data demonstrating the long-term benefit of treatment with VOXZOGO® (vosoritide) and new observational data on disease burden in children with achondroplasia.

Edgewise Therapeutics, Inc. today announced that the company will present on EDG-5506 at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference.

9 Meters Biopharma, Inc. announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of 3,125,000 shares of the Company’s common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock.

Eureka Therapeutics, Inc. today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka’s proprietary ARTEMIS ® T-cell receptor platform.

Catamaran Bio Inc. and OmniaBio Inc. today announced their partnership to develop and manufacture Catamaran Bio’s allogeneic chimeric antigen receptor (CAR)-NK cell therapies for the treatment of solid tumors.

Direct Biologics, LLC announced favorable safety, dosing and efficacy results from its Phase 2 clinical trial of ExoFlo™ in hospitalized adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS).

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 3:00 p.m. ET.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role.

Nanalysis Scientific Corp. announces that the Company’s Board of Directors has granted 335,000 stock options to Directors and Officers of the Company, pursuant to the Company’s stock option plan.

Mirum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved a reduction in age from one year to three months for LIVMARLI® oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome.